HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The multifaceted therapeutic potential of benfotiamine.

Abstract
Thiamine, known as vitamin B(1), plays an essential role in energy metabolism. Benfotiamine (S-benzoylthiamine O-monophoshate) is a synthetic S-acyl derivative of thiamine. Once absorbed, benfotiamine is dephosphorylated by ecto-alkaline phosphatase to lipid-soluble S-benzoylthiamine. Transketolase is an enzyme that directs the precursors of advanced glycation end products (AGEs) to pentose phosphate pathway. Benfotiamine administration increases the levels of intracellular thiamine diphosphate, a cofactor necessary for the activation transketolase, resulting in the reduction of tissue level of AGEs. The elevated level of AGEs has been implicated in the induction and progression of diabetes-associated complications. Chronic hyperglycemia accelerates the reaction between glucose and proteins leading to the formation of AGEs, which form irreversible cross-links with many macromolecules such as collagen. In diabetes, AGEs accumulate in tissues at an accelerated rate. Experimental studies have elucidated that binding of AGEs to their specific receptors (RAGE) activates mainly monocytes and endothelial cells and consequently induces various inflammatory events. Moreover, AGEs exaggerate the status of oxidative stress in diabetes that may additionally contribute to functional changes in vascular tone control observed in diabetes. The anti-AGE property of benfotiamine certainly makes it effective for the treatment of diabetic neuropathy, nephropathy and retinopathy. Interestingly, few recent studies demonstrated additional non-AGE-dependent pharmacological actions of benfotiamine. The present review critically analyzed the multifaceted therapeutic potential of benfotiamine.
AuthorsPitchai Balakumar, Ankur Rohilla, Pawan Krishan, Ponnu Solairaj, Arunachalam Thangathirupathi
JournalPharmacological research (Pharmacol Res) Vol. 61 Issue 6 Pg. 482-8 (Jun 2010) ISSN: 1096-1186 [Electronic] Netherlands
PMID20188835 (Publication Type: Journal Article, Review)
Copyright(c) 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • Thiamine
  • benphothiamine
Topics
  • Animals
  • Diabetes Mellitus (drug therapy)
  • Glycation End Products, Advanced (antagonists & inhibitors, metabolism)
  • Humans
  • Hyperglycemia (drug therapy)
  • Hypoglycemic Agents (pharmacology, therapeutic use)
  • Thiamine (analogs & derivatives, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: